Cesium 131 versus iodine 125 implants for prostate cancer: Evaluation of early PSA response

Canadian Journal of Urology

Volumn 17, Issue 5, 2010, Pages 5360-5364

  Tomaszewski, Jeffrey J ^a   Smaldone, Marc C ^a   Makaroun, Sami ^a   Smith, Ryan P ^a   Beriwal, Sushil ^a   Benoit, Ronald M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cesium; Prostate adenocarcinoma; Prostate brachytherapy; PSA

Indexed keywords

CESIUM; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; BRACHYTHERAPY; COMPARATIVE STUDY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; RADIATION EXPOSURE; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; CESIUM RADIOISOTOPES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 79952276881     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Norderhaug I, Dahl O, Hoisaeter PA et al. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness. Eur Urol 2003;44(1):40-46.
2. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51(1):31-40.
3. Peschel RE, Colberg JW. Surgery, brachytherapy, and externalbeam radiotherapy for early prostate cancer. Lancet Oncol 2003;4(4):233-241.
4. Bice WS, Prestidge BR, Kurtzman SM et al. Recommendations for permanent prostate brachytherapy with (131)Cs: a consensus report from the Cesium Advisory Group. Brachytherapy 2008;7(4):290-296.
5. Wang JZ, Mayr NA, Nag S et al. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy. Med Phys 2006;33(4):1025-1032.
6. Murphy MK, Piper RK, Greenwood LR et al. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med Phys 2004;31(6):1529-1538.
7. Rivard MJ. Brachytherapy dosimetry parameters calculated for a 131Cs source. Med Phys 2007;34(2):754-762.
8. Wittman RS, Fisher DR. Multiple-estimate monte carlo calculation of the dose rate constant for a cesium-131 interstitial brachytherapy seed. Med Phys 2007;34(1):49-54.
9. Yue N, Heron DE, Komanduri K, Huq MS. Prescription dose in permanent (131)Cs seed prostate implants. Med Phys 2005;32(8):2496-2502.
10. Merrick GS, Butler WM, Wallner KE et al. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. Brachytherapy 2003;2(3):181-188.
11. Miller N, Smolkin ME, Bissonette E, Theodorescu D. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Cancer 2005;103(12):2499-2506.
12. Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF Jr, Fuks Z. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol 1995;13(2):459-463.
13. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-974.
14. Aaltomaa SH, Kataja VV, Lahtinen T, Palmgren JE, Forsell T. Eight years experience of local prostate cancer treatment with permanent I (125) seed brachytherapy - Morbidity and outcome results. Radiother Oncol 2009;91(2):213-216.
15. Zerbib M, Zelefsky MJ, Higano CS, Carroll PR. Conventional treatments of localized prostate cancer. Urology 2008;72(6 Suppl): S25-S35.
16. Blaivas JG, Weiss JP, Jones M. The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer. BJU Int 2006;98(6):1233-7;discussion 7.
17. Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU Int 2006;98(5):979-981.
18. Crook J, Fleshner N, Roberts C, Pond G. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol 2008;179(1):141-145;discussion 6.
19. Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007;69(2):338-342.
20. Prestidge BR, Bice W.S., Jurkovic J et al. A multi-institutional phase II trial for cesium-131 permanent prostate brachytherapy. Brachytherapy 2006;5:79.
21. Prestidge B. R. BWS. Clinical outcomes of a phase II, multiinstitutional cesium-131 permanent prostate brachytherapy trial. Brachytherapy 2007;6:78.
22. Kattan MW, Fearn PA, Leibel S, Potters L. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2000;48(5):1469-1474.
23. Pellizzon AC, Salvajoli J, Novaes P, Maia M, Fogaroli R. Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int Braz J Urol 2008;34(3):293-301.
24. rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-974.
25. Crook J, Gillan C, Yeung I et al. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007;69(2):426-433.
26. rd, Merrick GS, Grimm P et al. Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of the Pro-Qura database. Am J Clin Oncol 2008;31(6):523-531.
27. Nickers P, Albert A, Waltregny D, Deneufbourg JM. Prognostic value of PSA nadir < or = 4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2006;65(1):73-77.